RXRX Jul 2024 11.000 put
| Previous close | 1.7100 |
| Open | 3.9200 |
| Bid | 2.0500 |
| Ask | 4.6000 |
| Strike | 11.00 |
| Expiry date | 2024-07-19 |
| Day's range | 3.9200 - 3.9200 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
GuruFocus.comInsider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc is a biotechnology firm that utilizes an AI-driven platform to accelerate drug discovery and development processes. Over the past year, Blake Borgeson has engaged in multiple transactions involving the company's stock, selling a total of 350,970 shares and making no purchases. Shares of Recursion Pharmaceuticals Inc were priced at $9.51 on the day of the transaction.
GlobeNewswireRecursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an add
GlobeNewswireRecursion Announces Proposed Offering of Class A Common Stock
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purch
